DEXYCU KIT
Clinical safety rating: caution
Comprehensive clinical and safety monograph for DEXYCU KIT (DEXYCU KIT).
Dexamethasone, a corticosteroid, suppresses inflammation by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis. It also decreases capillary permeability, fibrin deposition, and immune cell migration.
| Metabolism | Primarily hepatic via CYP3A4; dexamethasone is a substrate of CYP3A4 and can induce its own metabolism with chronic use. |
| Excretion | Primarily eliminated via hepatic metabolism; negligible renal or biliary excretion of unchanged drug. Intracameral dexamethasone is absorbed systemically and metabolized in the liver, with metabolites excreted in urine (<5% unchanged) and feces. Total body clearance is approximately 0.2 L/h/kg. |
| Half-life | The terminal elimination half-life of dexamethasone after intracameral administration is approximately 3-4 hours in the aqueous humor, contributing to rapid clearance from the eye. Systemic half-life ranges from 1.8 to 3.5 hours due to metabolism. |
| Protein binding | Approximately 77-80% bound to plasma proteins, primarily albumin. Dexamethasone binding is concentration-independent. |
| Volume of Distribution | Volume of distribution for dexamethasone is approximately 0.5-1.0 L/kg (total body water), indicating extensive tissue distribution. After intracameral injection, the Vd in the eye is confined to the anterior chamber volume (~0.25 mL). |
| Bioavailability | Intracameral administration results in 100% bioavailability locally. Systemic bioavailability is negligible due to the small dose (342 mcg) and extensive first-pass metabolism. Oral bioavailability of dexamethasone is approximately 60-70%. |
| Onset of Action | Onset of action is immediate upon intracameral injection; clinical effect (reduction of inflammation) is typically observed within 24 hours post-administration. |
| Duration of Action | The duration of action is sustained for up to 22 days as a single dose, due to the sustained-release formulation. Clinical efficacy in suppressing postoperative inflammation is maintained throughout the 3-week postoperative period. |
1% (dexamethasone 1 mg) intracameral injection administered as a single dose at the end of cataract surgery.
| Dosage form | SUSPENSION |
| Renal impairment | No specific dose adjustment is recommended for patients with renal impairment, as dexamethasone is metabolized in the liver. |
| Liver impairment | No specific dose adjustment is recommended for patients with hepatic impairment, but caution is advised due to potential altered metabolism. |
| Pediatric use | Safety and efficacy in pediatric patients have not been established; no specific dosing guidelines available. |
| Geriatric use | No specific dose adjustment is required for geriatric patients; however, consider the overall health status and potential for increased intraocular pressure. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for DEXYCU KIT (DEXYCU KIT).
| Breastfeeding | Systemic dexamethasone is excreted in breast milk. After intraocular injection, systemic concentrations are below limits of quantification, making transfer to infant negligible. M/P ratio is not determinable due to undetectable plasma levels. Use is considered compatible with breastfeeding. |
| Teratogenic Risk | DEXYCU (dexamethasone intraocular suspension) 9% is administered as a single-dose intraocular injection for postoperative inflammation. Systemic absorption is minimal following ocular administration. Based on corticosteroid class, first trimester use is associated with increased risk of cleft palate (2-3x background). Second and third trimester exposure may cause fetal adrenal suppression, growth restriction, and oligohydramnios. However, intraocular route results in negligible systemic levels, likely minimizing fetal risk. No adequate human studies exist; animal studies show teratogenicity with systemic corticosteroids. |
■ FDA Black Box Warning
Not available (DEXYCU does not have an FDA boxed warning).
| Serious Effects |
["Hypersensitivity to dexamethasone or any component of the formulation","Active ocular infection (bacterial, viral, fungal, mycobacterial)","Epithelial herpes simplex keratitis (dendritic keratitis)"]
| Precautions | ["Increased intraocular pressure (IOP); monitor IOP regularly","Risk of secondary ocular infection (including fungal, viral) due to immunosuppression","Delayed wound healing","Corticosteroid-induced cataract formation with prolonged use","Systemic absorption may cause adrenal suppression, especially with prolonged or high-dose use"] |
Loading safety data…
| Fetal Monitoring | Monitor intraocular pressure post-injection. No specific fetal monitoring required due to minimal systemic absorption. In patients receiving systemic corticosteroids, monitor for gestational diabetes, hypertension, and fetal growth. |
| Fertility Effects | No studies on fertility effects of intraocular dexamethasone. Systemic corticosteroids may alter menstrual cyclicity and reduce fertility; topical ocular use unlikely to affect fertility due to negligible systemic exposure. |